Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Kidney Disease Investigation(Electronic Edition) ›› 2025, Vol. 14 ›› Issue (03): 158-163. doi: 10.3877/cma.j.issn.2095-3216.2025.03.007

• Reviews • Previous Articles     Next Articles

Research progress on preventing and treating renal fibrosis by intervening in classical TGF-β/Smad signaling pathway

Shanshan Liu1, Xiaojiao Zhao1, Yufeng Qiao1,()   

  1. 1. Department of Nephrology,Shanxi Provincial People′s Hospital Affiliated to Shanxi Medical University,Taiyuan 030001,Shanxi Province,China
  • Received:2024-11-13 Online:2025-06-28 Published:2025-07-09
  • Contact: Yufeng Qiao

Abstract:

Renal fibrosis is the end-stage manifestation of chronic kidney disease, with a complex mechanism involving multiple pathogenic mechanisms and signaling pathways.The signaling pathways include classical transforming growth factor-β (TGF-β)/mammals maternal against decapentaplegic (Smad)pathway, non-classical TGF-β/Smad pathway, and wingless/integrated (Wnt) gene/β-catenin pathway.The pathogenesis mainly includes excessive deposition of extracellular matrix as well as transformation and activation of myofibroblasts.This article started with the classic TGF-β/Smad signaling pathway and reviewed the relevant clinical trials and preclinical research progress, aiming to provide new ideas and references for preventing and treating renal fibrosis.

Key words: Renal fibrosis, Chronic kidney disease, Transforming growth factor-β (TGF-β), Mammals maternal against decapentaplegic (Smad) protein, Signaling pathway

京ICP 备07035254号-35
Copyright © Chinese Journal of Kidney Disease Investigation(Electronic Edition), All Rights Reserved.
Tel: 010-66937011 E-mail: zhsbyj@126.com
Powered by Beijing Magtech Co. Ltd